Home
Atlas
Insights
Docs
Sign in

© 2026 Lanfrica. All rights reserved. All copyrights of the resources shown on the Lanfrica website belong to the original copyright holders, unless explicitly stated otherwise.

Baseline CD4 and mortality trends in the South African human immunodeficiency virus programme: Analysis of routine data

Creator:

RivKatMoyJam

Publisher:

AOS

Host:

Visit

Licenses

https://creativecommons.org/licenses/by/4.0

Similar

Reduction in Baseline CD4 Count Testing Following Human Immunodeficiency Virus “Treat All” Adoption in UgandaSEARCH Human Immunodeficiency Virus (HIV) Streamlined Treatment Intervention Reduces Mortality at a Population Level in Men With Low CD4 CountsRetrospective analysis of CD4 count trends in South AfricaBaseline characteristics of the HOMINY (human papillomavirus, human immunodeficiency virus, and oral microbiota interplay in Nigerian youth) prospective longitudinal cohortCost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalenceImmunodeficiency and Cancer in 3.5 Million People Living With Human Immunodeficiency Virus (HIV): The South African HIV Cancer Match Study

Reduction in Baseline CD4 Count Testing Following Human Immunodeficiency Virus “Treat All” Adoption in Uganda

Abstract Baseline CD4 testing rates declined from 73% to 21% between 2013 and 2018

SEARCH Human Immunodeficiency Virus (HIV) Streamlined Treatment Intervention Reduces Mortality at a Population Level in Men With Low CD4 Counts

Abstract Background We tested the hypothesi

Retrospective analysis of CD4 count trends in South Africa

Background: South Africa has the largest HIV epidemic globally. Despite the scale-up of antiretrovir

Baseline characteristics of the HOMINY (human papillomavirus, human immunodeficiency virus, and oral microbiota interplay in Nigerian youth) prospective longitudinal cohort

Background The HOMINY (Human Papillomavirus, Human Immunodeficiency Virus, and

Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence

Abstract Background This study aims at evaluating the cost-effectiveness of a 2-dose schedule human

Immunodeficiency and Cancer in 3.5 Million People Living With Human Immunodeficiency Virus (HIV): The South African HIV Cancer Match Study

Abstract Background We analyzed association